{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:10:26Z","timestamp":1768525826853,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["20K09829"],"award-info":[{"award-number":["20K09829"]}]},{"name":"Alcon Pharma Research Grants"},{"name":"The Foundation for The Advancement of Clinical Medicine"},{"name":"NIH","award":["EY30141"],"award-info":[{"award-number":["EY30141"]}]},{"name":"William Keck Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00417-023-06018-z","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T08:02:36Z","timestamp":1677916956000},"page":"2189-2197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Persistence of vascular empty sleeves in choroidal neovascularization after VEGF therapy in both animal models and humans"],"prefix":"10.1007","volume":"261","author":[{"given":"Iori","family":"Wada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4200-0052","authenticated-orcid":false,"given":"Shintaro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Shiose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunobu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"key":"6018_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-018-0623-4","author":"Y Morizane","year":"2018","unstructured":"Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, Shiraga F (2018) Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-018-0623-4","journal-title":"Jpn J Ophthalmol"},{"key":"6018_CR2","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606\u20132617. https:\/\/doi.org\/10.1056\/NEJMra0801537","journal-title":"N Engl J Med"},{"key":"6018_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10384-021-00869-x","volume":"65","author":"K Yamashiro","year":"2021","unstructured":"Yamashiro K, Oishi A, Hata M, Takahashi A, Tsujikawa A (2021) Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Jpn J Ophthalmol 65:741\u2013760. https:\/\/doi.org\/10.1007\/s10384-021-00869-x","journal-title":"Jpn J Ophthalmol"},{"key":"6018_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10384-021-00890-0","volume":"66","author":"H Tamura","year":"2022","unstructured":"Tamura H, Akune Y, Hiratsuka Y, Kawasaki R, Kido A, Miyake M, Goto R, Yamada M (2022) Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI. Jpn J Ophthalmol 66:19\u201332. https:\/\/doi.org\/10.1007\/s10384-021-00890-0","journal-title":"Jpn J Ophthalmol"},{"issue":"209\u2013213","key":"6018_CR5","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/j.ajo.2011.10.016","volume":"153","author":"SB Bloch","year":"2012","unstructured":"Bloch SB, Larsen M, Munch IC (2012) Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol 153(209\u2013213):e202. https:\/\/doi.org\/10.1016\/j.ajo.2011.10.016","journal-title":"Am J Ophthalmol"},{"key":"6018_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/00006982-200512000-00016","volume":"25","author":"D Pauleikhoff","year":"2005","unstructured":"Pauleikhoff D (2005) neovascular age-related macular degeneration: natural history and treatment outcomes. Retina 25:1065\u20131084. https:\/\/doi.org\/10.1097\/00006982-200512000-00016","journal-title":"Retina"},{"key":"6018_CR7","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW (2021) Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res 82:100906. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100906","journal-title":"Prog Retin Eye Res"},{"key":"6018_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nrclinonc.2012.120","volume":"9","author":"A Albini","year":"2012","unstructured":"Albini A, Tosetti F, Li VW, Noonan DM, Li WW (2012) Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 9:498\u2013509. https:\/\/doi.org\/10.1038\/nrclinonc.2012.120","journal-title":"Nat Rev Clin Oncol"},{"key":"6018_CR9","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1158\/0008-5472.CAN-11-3406","volume":"72","author":"B Sitohy","year":"2012","unstructured":"Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF\/VEGFR therapy for cancer: reassessing the target. Cancer Res 72:1909\u20131914. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3406","journal-title":"Cancer Res"},{"key":"6018_CR10","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM, O\u2019Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610\u20132621. https:\/\/doi.org\/10.1172\/JCI24612","journal-title":"J Clin Invest"},{"key":"6018_CR11","doi-asserted-by":"publisher","unstructured":"Shah RS, Soetikno BT, Lajko M, Fawzi AA (2015) A mouse model for laser-induced choroidal neovascularization. J Vis Exp: e53502 https:\/\/doi.org\/10.3791\/53502","DOI":"10.3791\/53502"},{"key":"6018_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.celrep.2015.01.050","volume":"10","author":"S Zandi","year":"2015","unstructured":"Zandi S, Nakao S, Chun KH, Fiorina P, Sun D, Arita R, Zhao M, Kim E, Schueller O, Campbell S, Taher M, Melhorn MI, Schering A, Gatti F, Tezza S, Xie F, Vergani A, Yoshida S, Ishikawa K, Yamaguchi M, Sasaki F, Schmidt-Ullrich R, Hata Y, Enaida H, Yuzawa M, Yokomizo T, Kim YB, Sweetnam P, Ishibashi T, Hafezi-Moghadam A (2015) ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. Cell Rep 10:1173\u20131186. https:\/\/doi.org\/10.1016\/j.celrep.2015.01.050","journal-title":"Cell Rep"},{"key":"6018_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"6018_CR14","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US (2013) Seven-year outcomes in ranibizumab-treated patients in Anchor, Marina, and Horizon: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292\u20132299. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046","journal-title":"Ophthalmology"},{"key":"6018_CR15","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00417-019-04361-8","volume":"257","author":"I Wada","year":"2019","unstructured":"Wada I, Oshima Y, Shiose S, Kano K, Nakao S, Kaizu Y, Yoshida S, Ishibashi T, Sonoda KH (2019) Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefes Arch Clin Exp Ophthalmol 257:1411\u20131418. https:\/\/doi.org\/10.1007\/s00417-019-04361-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6018_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","volume":"6","author":"TA Ciulla","year":"2022","unstructured":"Ciulla TA, Hussain RM, Taraborelli D, Pollack JS, Williams DF (2022) Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 Eyes. Ophthalmol Retina 6:796\u2013806. https:\/\/doi.org\/10.1016\/j.oret.2022.03.021","journal-title":"Ophthalmol Retina"},{"key":"6018_CR17","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1097\/IAE.0000000000000836","volume":"35","author":"NW Muakkassa","year":"2015","unstructured":"Muakkassa NW, Chin AT, de Carlo T, Klein KA, Baumal CR, Witkin AJ, Duker JS, Waheed NK (2015) Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina 35:2252\u20132259. https:\/\/doi.org\/10.1097\/IAE.0000000000000836","journal-title":"Retina"},{"key":"6018_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000487611","volume":"240","author":"J Takeuchi","year":"2018","unstructured":"Takeuchi J, Kataoka K, Ito Y, Takayama K, Yasuma T, Kaneko H, Terasaki H (2018) Optical coherence tomography angiography to quantify choroidal neovascularization in response to aflibercept. Ophthalmologica 240:90\u201398. https:\/\/doi.org\/10.1159\/000487611","journal-title":"Ophthalmologica"},{"key":"6018_CR19","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1096\/fj.14-251934","volume":"28","author":"D Sun","year":"2014","unstructured":"Sun D, Nakao S, Xie F, Zandi S, Bagheri A, Kanavi MR, Samiei S, Soheili ZS, Frimmel S, Zhang Z, Ablonczy Z, Ahmadieh H, Hafezi-Moghadam A (2014) Molecular imaging reveals elevated VEGFR-2 expression in retinal capillaries in diabetes: a novel biomarker for early diagnosis. FASEB J 28:3942\u20133951. https:\/\/doi.org\/10.1096\/fj.14-251934","journal-title":"FASEB J"},{"key":"6018_CR20","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","volume":"168","author":"N Jo","year":"2006","unstructured":"Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036\u20132053. https:\/\/doi.org\/10.2353\/ajpath.2006.050588","journal-title":"Am J Pathol"},{"key":"6018_CR21","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1167\/iovs.11-8114","volume":"53","author":"S Nakao","year":"2012","unstructured":"Nakao S, Zandi S, Lara-Castillo N, Taher M, Ishibashi T, Hafezi-Moghadam A (2012) Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration. Invest Ophthalmol Vis Sci 53:3296\u20133302. https:\/\/doi.org\/10.1167\/iovs.11-8114","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6018_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0002-9394(81)90230-0","volume":"91","author":"DB Archer","year":"1981","unstructured":"Archer DB, Gardiner TA (1981) Electron microscopic features of experimental choroidal neovascularization. Am J Ophthalmol 91:433\u2013457. https:\/\/doi.org\/10.1016\/0002-9394(81)90230-0","journal-title":"Am J Ophthalmol"},{"key":"6018_CR23","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.ajpath.2016.02.018","volume":"186","author":"K Strittmatter","year":"2016","unstructured":"Strittmatter K, Pomeroy H, Marneros AG (2016) Targeting platelet-derived growth factor receptor beta(+) scaffold formation inhibits choroidal neovascularization. Am J Pathol 186:1890\u20131899. https:\/\/doi.org\/10.1016\/j.ajpath.2016.02.018","journal-title":"Am J Pathol"},{"key":"6018_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10456-013-9402-5","volume":"17","author":"A Dong","year":"2014","unstructured":"Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog JK, Baumann M, Shen J, Iwase T, Tian J, Stevens R, Hackett SF, Stumpp MT, Campochiaro PA (2014) Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 17:553\u2013562. https:\/\/doi.org\/10.1007\/s10456-013-9402-5","journal-title":"Angiogenesis"},{"key":"6018_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1172\/JCI18549","volume":"112","author":"A Abramsson","year":"2003","unstructured":"Abramsson A, Lindblom P, Betsholtz C (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112:1142\u20131151. https:\/\/doi.org\/10.1172\/JCI18549","journal-title":"J Clin Invest"},{"key":"6018_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3928\/23258160-20170130-02","volume":"48","author":"EN Dunn","year":"2017","unstructured":"Dunn EN, Hariprasad SM, Sheth VS (2017) An overview of the Fovista and Rinucumab trials and the fate of anti-PDGF medications. Ophthalmic Surg Lasers Imaging Retina 48:100\u2013104. https:\/\/doi.org\/10.3928\/23258160-20170130-02","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6018_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY, Tenaya IL (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"6018_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ajpath.2015.11.014","volume":"186","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa K, Sreekumar PG, Spee C, Nazari H, Zhu D, Kannan R, Hinton DR (2016) alphaB-Crystallin regulates subretinal fibrosis by modulation of epithelial-mesenchymal transition. Am J Pathol 186:859\u2013873. https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.014","journal-title":"Am J Pathol"},{"key":"6018_CR29","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1167\/iovs.16-19204","volume":"57","author":"SJ Park","year":"2016","unstructured":"Park SJ, Choi Y, Na YM, Hong HK, Park JY, Park KH, Chung JY, Woo SJ (2016) Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model. Invest Ophthalmol Vis Sci 57:2612\u20132617. https:\/\/doi.org\/10.1167\/iovs.16-19204","journal-title":"Invest Ophthalmol Vis Sci"}],"updated-by":[{"DOI":"10.1007\/s00417-023-06214-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000}}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06018-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:04:04Z","timestamp":1692702244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06018-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6018"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06018-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00417-023-06214-x","asserted-by":"object"}]},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00417-023-06214-x","URL":"https:\/\/doi.org\/10.1007\/s00417-023-06214-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Care Committee of Kyushu University (A21-013). All experimental procedures on the animals were performed according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Moreover, this study was approved by the institutional ethics committees of Kyushu University Hospital (28\u2013473, UMIN 000028656), and was performed in accordance with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Shintaro Nakao: consulting fee by Kowa; travel reimbursements and speaker fees from Novartis, Bayer Pharma, Canon Inc., Santen Pharmaceutical, Kowa, Senju Pharmaceutical, Ono Pharmaceutical, and MSD. Koh-Hei Sonoda: consulting fees from Kowa, JT, and AbbVie; travel reimbursements and speaker fees from Novartis, Bayer Pharma, Canon Inc., Santen Pharmaceutical, Kowa, Senju Pharmaceutical, Ono Pharmaceutical, MSD, HOYA, Wakamoto, AMO, Alcon, Otsuka Pharmaceutical, AbbVie Eisai, Nidek, Topcon, Novo Nordisk, Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharma, and Astellas. The following authors have no financial disclosures: Iori Wada, Yosuke Fukuda, Satomi Shiose, Atsunobu Takeda, and Ram Kannan. All authors attest that they met the current ICMJE criteria for authorship.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}